Tofacitinib for hard-to-treat Blau syndrome
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests if the drug tofacitinib (a JAK inhibitor) can help people with Blau syndrome whose symptoms did not improve with other treatments. Blau syndrome is a rare genetic condition that causes inflammation in the skin, joints, eyes, and other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed NOD2 gene mutation.
- You have symptoms like skin rash, arthritis, eye inflammation, or lung involvement.
- You have tried at least one immunosuppressant or biologic for 12 weeks or more without success.
- You are not currently taking an IL-1 inhibitor or other biologic drugs.
- You are not pregnant or breastfeeding.
- You do not have severe organ failure or a life expectancy under 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug that blocks inflammation in people with Blau syndrome, a rare genetic condition causing joint, eye, and skin problems. The goal is to see if the drug can reduce symptoms and improve quality of life.
This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
Hear when a new Blau Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.